Citation Impact
Citing Papers
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
2015
Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study
2021 Standout
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
2013
Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
2019
CONSORT 2010 statement: extension to randomised pilot and feasibility trials
2016 Standout
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
2008 Standout
American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis
2011 Standout
Infections in patients with rheumatoid arthritis treated with biologic agents
2005
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004
2004
Rheumatoid arthritis
2016 Standout
Why Most Published Research Findings Are False
2005 Standout
Undiagnosed connective tissue diseases
2016
Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future
2012
Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
2009
What is “quality of evidence” and why is it important to clinicians?
2008 Standout
The assessment of the patient with systemic sclerosis
2003
Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society
2007 Standout
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo
2009
Impact of Hallmark Autoantibody Reactivity on Early Diagnosis in Scleroderma
2012
Treatment With Immunosuppressive and Disease Modifying Drugs During Pregnancy and Lactation
1992
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies
2014 Standout
Definitions and Diagnosis of Pulmonary Hypertension
2013 Standout
Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection
2003
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
2005 Standout
Granulocyte chemotaxis and disease expression are differentially regulated by GRK subtype in an acute inflammatory arthritis model (K/BxN)
2008 StandoutNobel
Cellular microchimerism as a lifelong physiologic status in parous women: An immunologic basis for its amplification in patients with systemic sclerosis
2003
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
2005
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)
2002
Systemic sclerosis
2017 Standout
Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre
2013
Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
2007 Standout
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
Consort 2010 statement: extension to cluster randomised trials
2012 Standout
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
2005 Standout
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
2010 Standout
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
2020 Standout
Investigation of a Unique Time-Space Cluster of Sarcoidosis in Firefighters
1993
Signalling pathways of the TNF superfamily: a double-edged sword
2003 Standout
Wegener Granulomatosis: An Analysis of 158 Patients
1992 Standout
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
2014
Inflammatory Bowel Disease
2002 Standout
Caspase Functions in Cell Death and Disease
2013 Standout
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: Results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trial
2002
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group
2011
REMISSION IN A PROSPECTIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS. AMERICAN RHEUMATISM ASSOCIATION PRELIMINARY REMISSION CRITERIA IN RELATION TO THE DISEASE ACTIVITY SCORE
1995
Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis
2013
Infliximab
2000
Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), Physician‐ and Patient‐Rated Global Assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS)
2011
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Validity of two new patient‐reported outcome measures in systemic sclerosis: Patient‐reported outcomes measurement information system 29‐item health profile and functional assessment of chronic illness therapy–dyspnea short form
2011
Etanercept
2002
Sarcoidosis
1997 Standout
Rheumatoid arthritis
2010 Standout
Phantom auditory perception (tinnitus): mechanisms of generation and perception
1990 Standout
Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk
2004
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
Reporting of Noninferiority and Equivalence Randomized Trials
2012 Standout
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
2007 Standout
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
2003
Systemic sclerosis
2015
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies
2006 Standout
IMMUNOPATHOGENESIS OF SYSTEMIC SCLEROSIS
1996
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
2015
Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis
2015
Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration
2008 Standout
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
2004
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
2019 Standout
Serum gold concentrations during treatment with auranofin
1987
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments]
1996 Standout
Actinomyces and Related Organisms in Human Infections
2015 Standout
CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
2010 Standout
Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis
2014
Marrow Transplantation for Thalassemiaa
1985 StandoutNobel
Nonpharmacologic Therapies for Acute and Chronic Low Back Pain: A Review of the Evidence for an American Pain Society/American College of Physicians Clinical Practice Guideline
2007 Standout
Course of Crohn's disease after allogeneic marrow transplantation
1998
Guidelines on the use of antirheumatic drugs in women during pregnancy and child-bearing age
1990
Inflammatory Bowel Disease
2010 Standout
Assessment of disease activity.
2003
Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis
2016
Following the Molecular Pathways toward an Understanding of the Pathogenesis of Systemic Sclerosis
2004 Standout
The gold complexes
1990
Methotrexate in Rheumatoid Arthritis
1987
BONE MARROW TRANSPLANTATION FOR INBORN ERRORS
1981
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
Gold Nanoparticles: A Revival in Precious Metal Administration to Patients
2011 Standout
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists
2014
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
2020 Standout
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
2010 Standout
Comparison of the Kinetics of Parenteral and Oral Gold
1983
A New Way of Thinking about Systemic Sclerosis: The Opportunity for a Very Early Diagnosis.
2016
Atomically Precise Clusters of Noble Metals: Emerging Link between Atoms and Nanoparticles
2017 Standout
Systematic reviews: CRD's guidance for undertaking reviews in health care
2010 Standout
Works of D.E. Furst being referenced
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group
2010
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards
2014
Development of a provisional core set of response measures for clinical trials of systemic sclerosis
2007
Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study
2011
Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis
2010
Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study
2009
High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis
2011
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
2010
Controversies in COX-2 inhibitor therapy: closing remarks.
2002
Single dose pharmacokinetics of auranofin in rheumatoid arthritis.
1982
Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis.
1999
Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.
1990
Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.
2001
New classification of antirheumatic drugs. The evolution of a concept.
1993
Gold pharmacokinetics in breast milk and serum of a lactating woman.
1987
OP0226 Expert consensus for performing right heart catheterization in suspicion of pulmonary arterial hypertension associated with systemic sclerosis: A delphi consensus study with cluster analysis from the eposs group
2012
Salicylate toxicity in elderly patients with rheumatoid arthritis.
1987
Case report: progressive systemic sclerosis-like syndrome after bone marrow transplantation. Clinical, immunologic, and pathologic findings.
1980
Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease.
1997
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis.
1999
Analysis of elevated serum interleukin-6 levels in rheumatoid arthritis: correlation with erythrocyte sedimentation rate or C-reactive protein.
1994
Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritis.
1985